Depot haloperidol decanoate schizophrenia

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

Her total fluoxetine plus norfluoxetine level also meant that this patient had more serotonin uptake inhibition and more inhibition of CYP enzymes than occurs in the usual patient on 20 mg/day. 5,6   In fact, the magnitude of these effects produced by fluoxetine in this patient would be virtually the same as would be expected in the average patient on 40 mg/day. On 20 mg/day, the average patient achieves approximately 80% serotonin uptake inhibition and substantial inhibition of two drug metabolizing cytochrome P450 (CYP) enzymes: CYP 2D6 and CYP 2C19. 5-7

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [42] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and  mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 =  mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [43] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .

Depot haloperidol decanoate schizophrenia

depot haloperidol decanoate schizophrenia


depot haloperidol decanoate schizophreniadepot haloperidol decanoate schizophreniadepot haloperidol decanoate schizophreniadepot haloperidol decanoate schizophreniadepot haloperidol decanoate schizophrenia